A Phase II Exploratory, Multicentre, Open-label, Non-comparative Study of ZD1839 (Iressa) and Radiotherapy in the Treatment of Patients With Glioblastoma Multiforme

Exclusion Criteria

• •Have had prior radiation therapy, immunotherapy, gene therapy and/or chemotherapy for the glioblastoma
• •co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ
• •known severe hypersensitivity to ZD1839 or any of the excipients of this product.